Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Schinifoline** is a natural alkaloid, specifically a quinolinone derivative, originally isolated from Zanthoxylum schinifolium and also found in Zanthoxylum simulans and related species[2][6]. It is characterized chemically as 2-heptyl-1-methylquinolin-4-one (C17H23NO, MW 257.37). Schinifoline demonstrates cytotoxic activity and selective antibacterial properties, particularly against Gram-positive bacteria[6]. In preclinical studies, schinifoline has shown the ability to induce apoptosis, arrest the cell cycle (notably increasing G2/M phase), and sensitize cancer cells (such as A549 lung cancer cells) to radiation, enhancing radiosensitivity in vitro[1][6]. There are also reports of antifungal activity against Candida albicans[3]. Mechanistically, schinifoline’s effects are associated with cell cycle arrest and induction of apoptosis, but its precise molecular targets remain uncharacterized. No evidence to date supports clinical use; all information is derived from in vitro and preclinical studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on schinifoline.